Amiri-Kordestani L - Search Results

1

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.

Chang E, Zhou J, Song C, Gittleman H, Fernandes L, Weinstock C, Atkins MB, Agrawal S, Sridhara R, Gormley N, Tang S, Suzman DL, Amiri-Kordestani L, Kluetz PG, Pazdur R, Rini BI, McDermott DF, Regan MM. Chang E, et al. Clin Cancer Res. 2024 Aug 1;30(15):3282-3286. doi: 10.1158/1078-0432.CCR-23-3719. Clin Cancer Res. 2024. PMID: 38416426

2

Follicular dendritic cell sarcoma of the neck: case report and review of current diagnostic and management strategies.

Amiri-Kordestani L, Priebat D, Chia SH. Amiri-Kordestani L, et al. Ear Nose Throat J. 2010 Jul;89(7):E14-7. doi: 10.1177/014556131008900702. Ear Nose Throat J. 2010. PMID: 20628972 Free article.

3

Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

Fojo T, Amiri-Kordestani L, Bates SE. Fojo T, et al. J Natl Cancer Inst. 2011 Dec 7;103(23):1738-40. doi: 10.1093/jnci/djr386. Epub 2011 Nov 1. J Natl Cancer Inst. 2011. PMID: 22045362 Free PMC article. Review.

4

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL. Campia U, et al. Circulation. 2019 Mar 26;139(13):e579-e602. doi: 10.1161/CIR.0000000000000641. Circulation. 2019. PMID: 30786722 Free PMC article. Review.

5

Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives.

Amiri-Kordestani L, Beaver JA, Cortazar P. Amiri-Kordestani L, et al. Oncology (Williston Park). 2015 Nov;29(11):843-4, 846. Oncology (Williston Park). 2015. PMID: 26573064 Free article. No abstract available.

6

Inflammatory breast cancer: yet another risk of the obesity epidemic?

Amiri-Kordestani L, Kamangar F, Zujewski JA. Amiri-Kordestani L, et al. J Natl Cancer Inst. 2013 Sep 18;105(18):1340-2. doi: 10.1093/jnci/djt236. J Natl Cancer Inst. 2013. PMID: 24046389 No abstract available.

7

ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Robey RW, Massey PR, Amiri-Kordestani L, Bates SE. Robey RW, et al. Anticancer Agents Med Chem. 2010 Oct 1;10(8):625-33. doi: 10.2174/187152010794473957. Anticancer Agents Med Chem. 2010. PMID: 21189132 Free PMC article. Review.

8

Why do phase III clinical trials in oncology fail so often?

Amiri-Kordestani L, Fojo T. Amiri-Kordestani L, et al. J Natl Cancer Inst. 2012 Apr 18;104(8):568-9. doi: 10.1093/jnci/djs180. Epub 2012 Apr 6. J Natl Cancer Inst. 2012. PMID: 22491346 No abstract available.

9

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.

Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, Hughes P, Russell AM, Miksinski SP, Chen XH, McGuinn WD, Palmby T, Schrieber SJ, Liu Q, Wang J, Song P, Mehrotra N, Skarupa L, Clouse K, Al-Hakim A, Sridhara R, Ibrahim A, Justice R, Pazdur R, Cortazar P. Amiri-Kordestani L, et al. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. doi: 10.1158/1078-0432.CCR-14-0012. Epub 2014 May 30. Clin Cancer Res. 2014. PMID: 24879797 Clinical Trial.

10

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.

Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P. Amiri-Kordestani L, et al. Clin Cancer Res. 2014 Nov 1;20(21):5359-64. doi: 10.1158/1078-0432.CCR-14-1268. Epub 2014 Sep 9. Clin Cancer Res. 2014. PMID: 25204553 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters